The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for vatiquinone for the treatment of children and ...

The U.S. Food and Drug Administration (FDA) has accepted for filing PTC Therapeutics’ New Drug Application (NDA) for ...

PTC Therapeutics (PTCT) announced that the U.S. Food and Drug Administration, FDA, has accepted for filing the New Drug Application, NDA, for ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for vatiquinone for the treatment of ...

3. Vatiquinone for Friedreich's Ataxia: This treatment has shown promise, particularly for pediatric patients not approved for Skyclaris. An NDA submission is planned for late 2024. 4. Translarna ...

As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis. The FDA recently approved ...

Vatiquinone (EPI-743) is under development for the treatment of Alpers-Huttenlocher syndrome, Friedreich ataxia, inherited mitochondrial disorders including Leigh syndrome, Alpers syndrome, ...

09:24 EST PTC Therapeutics (PTCT) sees FY25 revenue $600M-$800M Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for ...

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients ...

PTC Therapeutics has cued up no fewer than three clinical trial readouts this quarter that could lead to new regulatory filings – but the latest for vatiquinone in inherited nerve disorder ...